7results about How to "Good clinical application value" patented technology

The invention belongs to the field of biological detection, and particularly relates to application of an ON detection reagent in auxiliary diagnosis of acute chest pain diseases. It is found that the ON protein is closely related to acute chest pain such as AAD, AMI and APE, the ON serves as a marker, a detection reagent of the ON is prepared into an auxiliary diagnosis product, and great clinical value and practical significance are achieved for early diagnosis and long-term prognosis of the three diseases (especially AAD) and improvement of life quality.

The present invention discloses an intestinal microbiota Bacteroides fragilis toxin-neutralizing nanobody and its application. By deeply studying the enterotoxigenic Bacteroides fragilis and the toxin BFT secreted by it in the bodies of patients with colorectal cancer and breast cancer, nanobodies against BFT are expressed by phage display technology; nanobodies with high binding affinity to the antigen are screened out through biopanning technology; a nanobody with the ability to neutralize the toxicity of BFT, also known as Nb2.43, is obtained. The present invention expresses and optimizes to obtain a BFT nanobody protein with high affinity, stability and uniformity, opening up a new field for the treatment of colorectal cancer and breast cancer with nanobodies targeting BFT, and having good research value and application prospects.

A rare earth organic tetrahedral molecular cage complex and a preparation method and application thereof are constructed with rare earth europium (III) as the vertex, triphenylamine-derived tripodal β-diketone as the face-directing ligand and 1,10-phenanthroline as the auxiliary ligand. The complex is modified by Pluronic F127 to obtain a composite material containing a rare earth organic tetrahedral molecular cage complex structure, and the application of the composite material as an inner ear drug carrier delivery system in the treatment of inner ear diseases. The complex of the present invention provides a cavity with a suitable capacity for accommodating guest molecules, and has high light efficiency to facilitate the tracing of drug carriers, and can efficiently penetrate the cochlear blood-membrane labyrinth barrier to enter the endolymph, and then be taken up by inner ear sensory cells. The Pluronic F127-modified rare earth cage complex synthesized by the present invention can be used as a safe and efficient inner ear drug delivery carrier, with great clinical value and application prospects.

This invention relates to the field of medical biopolymer materials technology, specifically to an injectable hydrogel for kidney stone removal, its preparation method, and its application. The preparation materials include at least a precursor solution 1 and a precursor solution 2. Precursor solution 1 contains at least a polyethylene glycol derivative and a thickener, while precursor solution 2 contains at least a polyamino polymer. By optimizing the formulation ratio of the two-component precursor solutions, a hydrogel with strong conformability, good toughness, and viscosity is formed in situ in the kidney stone area. This encapsulates the kidney stone, facilitating its removal from the body and avoiding the safety hazards associated with small kidney stone fragments or conventional drug treatment.

The present invention relates to the field of medicine, and discloses a novel endocrine therapy resistance marker for advanced prostate cancer and its application, wherein the marker is DENND3. The present invention first discovered that the expression level of the DENND3 gene in prostate cancer abiraterone-resistant cells is significantly higher than that in parental prostate cancer cells. Therefore, the determination of the expression level of the DENND3 gene can be used as a basis for judging the drug resistance / sensitivity of the user to abiraterone; the DENND3 gene-specific siRNAs provided by the present invention can efficiently inhibit or knock down the expression of the DENND3 gene in target cells, thereby promoting cell apoptosis, inhibiting the proliferation of abiraterone-resistant prostate cancer cells, and further inhibiting the growth of prostate cancer cells. Therefore, it can be used to prepare a drug that improves the resistance of prostate cancer to abiraterone, and has great clinical and economic value in the treatment of prostate cancer.

The present invention belongs to the field of biomedical detection technology, and in particular to a biomarker, a detection kit and an application for detecting high myopia complicated with choroidal neovascularization. The present invention discloses the application of tRF-22 in the preparation of a diagnostic reagent for high myopia complicated with choroidal neovascularization and a diagnostic kit for high myopia complicated with choroidal neovascularization. The present invention is verified by quantitative PCR and finds that tRF-22 is significantly correlated with the occurrence of high myopia complicated with choroidal neovascularization. The present invention utilizes real-time fluorescence quantitative PCR technology, and by detecting the relative content of tRF-22 in aqueous humor, it can be used for the screening of clinical patients with high myopia complicated with choroidal neovascularization, and provides a theoretical basis for the early intervention of high myopia complicated with choroidal neovascularization.

The invention discloses a high-risk coronary artery stenosis prediction method based on multi-level structure information collaboration, and belongs to the technical field of intelligent medical aid decision making. The method comprises the following steps: firstly, constructing a clinical pathological structure perception graph to describe a structure constraint relationship among variables, and constructing a patient group risk conduction graph to model risk association of patients in a multi-dimensional phenotypic space; then structure perception representation learning is carried out on the two images, and feature-level and patient-level embedded representations are obtained; and then realizing cross-level semantic alignment through linear projection, introducing a learnable weight to perform structure enhancement on the two types of representations, inputting the fused joint representation into a classifier, and outputting a risk prediction result of the high-risk coronary artery stenosis of the patient. According to the method, through double-graph collaborative modeling and multi-level structure information fusion, effective integration of heterogeneous structure characterization is realized, and the prediction accuracy and stability are improved.